The Naruto franchise has a story spanning over 26 seasons total between both the Naruto and Naruto Shippuden series. With such a high number of seasons, it’s only natural that there have been some ...

After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts. The biotech on Friday said 65% of its staffers are set to leave the company.

BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics ...

Travelers are chasing more than rest; they want lasting vitality. Alexandra Walterspiel is betting that the future of luxury lies in wellness, and her approach at Sensei hints at where high-end ...

Naruto is the quintessential underdog anime, but I think it’s safe to say there’s only one character who really meets that definition. It’ll come as no surprise that, like so many people, I would ...

Based on the extremely popular manga by Masashi Kishimoto, Naruto centers on its namesake, Naruto Uzumaki, and his friends as they strive to become the best ninjas in the village. Naruto's ultimate ...

The Naruto franchise features some of anime's most beloved teams and rivalries. From the titular protagonist and his best friend to the fan-favorite members of the Legendary Sanin, the world created ...

Lucas Kloberdanz-Dyck is a writer for Collider. He grew up creating lists, stories, and worlds, which led to his love of anime and video games. He attended Sheridan College where he earned an Honours ...

“He spoke to me about roles a few times over the years,” Pearce said when asked about his relationship with Nolan after the breakout success of “Memento.” “The first ‘Batman’ and ‘The Prestige.’ But ...

Dr. Adil Dalal, DBA - CEO, keynote speaker, leadership pioneer. Author of 4 books and 10 global awards, inspiring leaders worldwide. I believe that traditional leadership models—transactional, ...

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its immune checkpoint inhibitor through phase 2. The asset in question, dubbed ...